Table 2.
Detailed patient comorbidities for MHI Hospitalized group (overall, training, validation, and test subgroups) and the external validation cohort (MIMIC-IV)
| Overall | Training | Validation | Test | MIMIC-IV | |
|---|---|---|---|---|---|
| Number of patients | 76 680 | 53 724 | 7685 | 15 271 | 109 870 |
| Heart failure | 10 260 (13.4%) |
7214 (13.4%) |
999 (13.0%) |
2047 (13.4%) |
15 273 (13.9%) |
| Coronary artery disease | 54 725 (71.4%) |
38 362 (71.4%) |
5455 (71.0%) |
10 908 (71.4%) |
25 643 (23.3%) |
| Chronic obstructive pulmonary disease | 8952 (11.7%) |
6285 (11.7%) |
892 (11.6%) |
1775 (11.6%) |
10 479 (9.5%) |
| Hypertension | 48 285 (63.0%) |
33 777 (62.9%) |
4805 (62.5%) |
9703 (63.5%) |
60 705 (55.3%) |
| Diabetes | 20 682 (27.0%) |
14 507 (27.0%) |
2086 (27.1%) |
4089 (26.8%) |
25 630 (23.3%) |
| Stroke | 847 (1.1%) |
594 (1.1%) |
82 (1.1%) |
171 (1.1%) |
4589 (4.2%) |
| Dyslipidaemia | 50 978 (66.5%) |
35 688 (66.4%) |
5167 (67.2%) |
10 123 (66.3%) |
44 440 (40.4%) |
| Obesity | 20 621 (26.9%) |
14 520 (27.0%) |
2059 (26.8%) |
4042 (26.5%) |
15 003 (13.7%) |
| Chronic kidney disease | 10 360 (13.5%) |
7290 (13.6%) |
1049 (13.6%) |
2021 (13.2%) |
15 750 (14.3%) |
| Sleep apnoea | 4482 (5.8%) |
3122 (5.8%) |
458 (6.0%) |
902 (5.9%) |
11 101 (10.1%) |
| Hyperthyroidism | 358 (.5%) |
255 (.5%) |
32 (.4%) |
71 (.5%) |
1064 (1.0%) |
| Vascular disease | 8169 (10.7%) |
5694 (10.6%) |
829 (10.8%) |
1646 (10.8%) |
8021 (7.3%) |
MIMIC-IV, Medical Information Mart for Intensive Care-IV.